| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ACTA1 |
| Uniprot No | P68133 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 3-377aa |
| 氨基酸序列 | DEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVMSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWITKQEYDEAGPSIVHRKCF |
| 预测分子量 | 47.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ACTA1重组蛋白的示例参考文献(仅供参考，实际文献需通过学术数据库检索)：
---
1. **文献名称**: "Recombinant human α-skeletal muscle actin production in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 本研究描述了一种在大肠杆菌中高效表达重组人ACTA1蛋白的方法，通过优化密码子使用和纯化步骤获得高纯度蛋白，用于体外肌动蛋白聚合实验。
2. **文献名称**: "Functional characterization of pathogenic ACTA1 mutations using recombinant protein models"
**作者**: Johnson L, et al.
**摘要**: 通过表达携带不同致病突变的ACTA1重组蛋白，分析其聚合动力学和细胞骨架相互作用，揭示突变导致肌无力的分子机制。
3. **文献名称**: "Expression and purification of ACTA1 in mammalian cells for contractility assays"
**作者**: Lee S, et al.
**摘要**: 报道了在哺乳动物细胞中瞬时表达重组ACTA1的策略，并应用于心肌细胞收缩功能研究，验证其与野生型蛋白的功能差异。
4. **文献名称**: "ACTA1 recombinant protein as a tool for studying cytoskeletal dynamics"(综述)
**作者**: Brown K, et al.
**摘要**: 综述了重组ACTA1蛋白在细胞骨架动态研究中的应用，包括荧光标记技术、体外运动性实验及药物筛选平台开发。
---
**提示**：实际文献建议通过PubMed、Google Scholar等平台以关键词“ACTA1 recombinant protein”或“recombinant α-skeletal actin”检索，并筛选近年的研究或经典方法论论文。
ACTA1 recombinant protein is derived from the human ACTA1 gene, which encodes skeletal muscle alpha-actin, a key component of the sarcomere in skeletal muscle cells. As a member of the actin family, ACTA1 plays a critical role in muscle contraction by interacting with myosin to generate force. Mutations in the ACTA1 gene are associated with congenital myopathies, such as nemaline myopathy and actin-accumulation myopathy, making this protein a focal point for neuromuscular disease research.
Recombinant ACTA1 is produced using biotechnological methods, typically expressed in bacterial (e.g., E. coli) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. The purified protein retains functional properties, enabling studies on actin polymerization, cytoskeletal dynamics, and muscle cell mechanics. Researchers utilize it to investigate disease mechanisms, screen therapeutic compounds, or develop gene therapies targeting ACTA1-related disorders.
In drug discovery, ACTA1 recombinant protein serves as a tool to study interactions with potential small molecules or biologics designed to stabilize actin filaments or mitigate aggregation. It also aids in structural biology efforts, including cryo-EM or X-ray crystallography, to map mutation-induced conformational changes. Additionally, it supports diagnostic applications, such as antibody production for detecting actin abnormalities in patient samples.
The development of ACTA1 recombinant protein underscores its dual role in advancing basic science and translational medicine, bridging insights from molecular pathology to therapeutic innovation for muscle diseases.
×
